Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2000

View Archived Issues

Pharmacopeia achieves milestone in Schering collaboration

M.D. Anderson Cancer Center to guide arglabin preclinical studies

Partners lay the groundwork to begin clinical testing of novel anti-HCV agent

ISIS-5132 reduces target RNA levels in human study

DiagnoCure submits new file to support approval of ImmunoCyt

Progenics and ADARC advance HIV vaccine research

Avant Immunotherapeutics updates progress with CETi-1

SuperGen licenses VTA technology from Techniclone

Sangamo and Baxter to collaborate on novel vascular disease therapeutics

Protein Design Labs and Celltech Chiroscience enter antibody patent agreement

Patent and orphan drug status obtained for Inhale's alpha1-proteinase inhibitor

The Liposome Company submits additional Evacet data to FDA

New antiinflammatory agents from HMR (Aventis) act by inhibiting cell adhesion

Discovery and use of E6-binding polypeptides for suppressing tumor growth

Clomethiazole: use in spinal cord injury

Agonists and antagonists of orphanin FQ receptor prepared by Roche

Modifications of carbapenem nucleus an important area of research at Merck

Aryl pyridinyl thiazoles from Novartis useful for inflammatory or obstructive airways diseases

Oxazolidinones in development at AstraZeneca useful against resistant Gram-positive pathogens

FDA issues public health advisory for influenza drugs

Trileptal granted FDA approval for treatment of epilepsy

EpiGenesis and Chiesi enter license and development agreement for asthma therapy

Patent coverage granted for Cell Genesys's third-generation lentiviral vectors

Broad patent issued to IntraBiotics covering its protegrin analogues

Promising preclinical results with StressGen's stress proteins published

Pre- and postischemic treatment with FR-183998 cardioprotective in rat models

Vivus and AstraZeneca resolve Muse distribution agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...